Disclaimer: We may earn a commission if you make any purchase by clicking our links. Please see our detailed guide here.

Follow us on:

Indian Cos Missing the Bus on Vaccines, mRNA-based Technologies: Jefferies

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

Join the Opinion Leaders Network

Join the Techgenyz Opinion Leaders Network today and become part of a vibrant community of change-makers. Together, we can create a brighter future by shaping opinions, driving conversations, and transforming ideas into reality.

Vaccines and mRNA-based technologies have rapidly emerged as promising new therapeutic modalities, but Indian companies are lagging behind in adopting these innovation platforms.

A report by foreign brokerage Jefferies said that Indian companies are missing the bus on relatively low-risk innovation.

At a recent health conference in the US, several vaccine companies, including CureVac, Valneva, BioNtech and Novavax, set out their growth plans for a post-Covid world.

The report said that mass inoculation with mRNA vaccines has validated the mRNA technology and put vaccines in the spotlight. The companies set out plans to use mRNA technology/vaccines for other infectious diseases, such as flu and Chikungunya, and in oncology.

“Our impression is that mRNA technology is widely available beyond the two major mRNA Covid vaccine producers. With the success of the Covid vaccines, conventional long timelines to vaccine approvals are likely to shorten and regulators should also accelerate the approval process,” Jefferies said.

“India’s vaccine deficit has provided a ready market for Indian companies to recoup initial investments in mRNA/vaccines. The existing commercial producers have been quick to scale up mRNA vaccines and a 30,000-subject India Covid trial costs $20 million, as per our estimate,” it added.

“Despite these advantages in a potential growth segment, the companies we cover, apart from Cadila, have shown a lack of interest in seeding these relatively low-risk opportunities,” Jefferies said in the note.

It said vaccines and mRNA-based technologies have rapidly emerged as promising new therapeutic modalities. Indian companies are lagging behind in adopting these innovation platforms, despite Covid-19 providing a mode of entry, it added.

Partner With Us

Digital advertising offers a way for your business to reach out and make much-needed connections with your audience in a meaningful way. Advertising on Techgenyz will help you build brand awareness, increase website traffic, generate qualified leads, and grow your business.

Join 10,000+ Fellow Readers

Get Techgenyz’s roundup delivered to your inbox curated with the most important for you that keeps you updated about the future tech, mobile, space, gaming, business and more.


Find Apps

The Ultimate Hub for Discovering Apps Unlock a world of apps: your ultimate hub for exploring and discovering limitless possibilities for on your every needs.

Power Your Business

Solutions you need to super charge your business and drive growth

More from this topic